Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 18Melanoma 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Esophageal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 9Breast Neoplasms 8Head and Neck Neoplasms 6Esophageal Squamous Cell Carcinoma 6Rectal Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Recurrence 4Neoplasms 4Carcinoma, Renal Cell 4Brain Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Radiation Pneumonitis 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oropharyngeal Neoplasms 2

Interventions

trifluridine tipiracil drug combination 1camrelizumab 1anlotinib 1Radiotherapy 1Induction Chemotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × ESCC × Immunotherapy × Clear all
NCT07015489 2025-06-11

Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Completed
44 enrolled

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡